JP2002180082A - Intake material - Google Patents
Intake materialInfo
- Publication number
- JP2002180082A JP2002180082A JP2000375386A JP2000375386A JP2002180082A JP 2002180082 A JP2002180082 A JP 2002180082A JP 2000375386 A JP2000375386 A JP 2000375386A JP 2000375386 A JP2000375386 A JP 2000375386A JP 2002180082 A JP2002180082 A JP 2002180082A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- oils
- fats
- dmct
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、トリグリセリドの
２位にω−３脂肪酸が結合し、かつトリグリセリドの
１、３位に中鎖脂肪酸が結合する油脂の摂取物に関す
る。TECHNICAL FIELD The present invention relates to an ingestion of fats and oils in which an ω-3 fatty acid is bonded to the 2-position of triglyceride, and a medium-chain fatty acid is bonded to positions 1 and 3 of the triglyceride.
【０００２】[0002]
【従来の技術および発明が解決しようとする課題】ドコ
サヘキサエン酸やエイコサペンタエン酸などのω−３脂
肪酸は、アラキドン酸を始めとするω−６脂肪酸と対比
して、その生理作用が１９７０年代後半から研究されて
きた。その生理作用は幅広く多岐に渡っており、脂質代
謝改善作用、抗動脈硬化作用、血圧低下作用、抗アレル
ギー作用、抗腫瘍作用、抗痴呆作用などを有することが
各種論文ならびに学会などで報告され、それを契機にω
−３脂肪酸を医薬品、特定保健用食品や健康食品などへ
利用することが検討されてきた。実際、イワシなどの青
物魚などから、エイコサペンタエン酸を１８〜２８％及
びドコサヘキサエン酸を８〜１６％含有する魚油や、マ
グロなどの回遊魚などから、ドコサヘキサエン酸を２０
〜３０％及びエイコサペンタエン酸を６〜１２％含有す
るマグロ油などが、軟カプセルに充填され健康食品とし
て広く流通している他、魚油から特異的にエイコサペン
タエン酸をエチルエステル誘導体として９０％以上に濃
縮した化合物が、閉塞性動脈硬化症や高脂血症の治療薬
として上市されている。2. Description of the Related Art ω-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid have a physiological action since the late 1970's in comparison with ω-6 fatty acids such as arachidonic acid. Has been studied. Its physiological effects are wide and diverse, and it has been reported in various papers and academic societies that it has lipid metabolism improving effect, anti-atherosclerotic effect, blood pressure lowering effect, anti-allergic effect, anti-tumor effect, anti-dementia effect, etc. Ω
Utilization of -3 fatty acids in pharmaceuticals, foods for specified health use, health foods, and the like has been studied. Actually, docosahexaenoic acid is contained in fish oil containing 18 to 28% of eicosapentaenoic acid and 8 to 16% of docosahexaenoic acid from migrating fish such as sardines and migrating fish such as tuna.
Tuna oil containing up to 30% and eicosapentaenoic acid in a content of 6 to 12% is widely distributed as a health food filled in soft capsules. In addition, eicosapentaenoic acid is specifically used as an ethyl ester derivative in fish oil in an amount of 90% or more. Are concentrated on the market as therapeutic agents for arteriosclerosis obliterans and hyperlipidemia.
【０００３】また、最近では、粉ミルクを初めとして、
清涼飲料水やパンなどの食品に、ドコサヘキサエン酸や
エイコサペンタエン酸などのω−３脂肪酸を含む油脂を
添加するなど、昨今の健康ブームと相まって、その機能
性を前面に掲げた食品の開発が盛んに行われており、健
康の維持・増進を目的に、いろいろな形態でドコサヘキ
サエン酸やエイコサペンタエン酸などのω−３脂肪酸を
含む油脂が摂取できる状況になりつつある。[0003] Recently, starting with powdered milk,
In conjunction with the recent health boom, foods such as soft drinks and breads are added with oils and fats containing ω-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid. In order to maintain and promote health, it is becoming possible to ingest oils and fats containing ω-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid in various forms.
【０００４】しかしながら、上述のドコサヘキサエン酸
やエイコサペンタエン酸などのω一３脂肪酸は、それを
含む魚油やマグロ油では、通常、パルミチン酸、パルミ
トオレイン酸、オレイン酸あるいはリノール酸などの長
鎖脂肪酸と共にトリグリセリド体を構成しており、その
体内への吸収性はそれ程十分ではない。即ち、ドコサヘ
キサエン酸やエイコサペンタエン酸などのω−３脂肪酸
を含む魚油やマグロ油を摂取した場合、十二指腸におい
て、分泌された胆汁酸などにより胆汁酸混合ミセルが形
成され、さらに膵リパーゼによるトリグリセリドの１、
３位の加水分解を経て、ドコサヘキサエン酸やエイコサ
ペンタエン酸などのω−３脂肪酸は、遊離脂肪酸の形あ
るいはモノグリセリドの形で腸管からリンパ管に吸収さ
れるという経路をたどるが、実際には、不完全なミセル
形成やリパーゼの基質特異性の問題などから、魚油やマ
グロ柚のドコサヘキサエン酸やエイコサペンタエン酸な
どのω−３脂肪酸の腸管からの吸収率はそれ程高くはな
い。[0004] However, the above-mentioned ω-13 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid are usually used in fish oil and tuna oil containing them in long-chain fatty acids such as palmitic acid, palmito oleic acid, oleic acid or linoleic acid. Together form a triglyceride, and its absorbability in the body is not so good. That is, when fish oil or tuna oil containing ω-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid is ingested, bile acid mixed micelles are formed in the duodenum by secreted bile acids and the like, and triglyceride by pancreatic lipase is further reduced to one. ,
After hydrolysis at the 3-position, omega-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid follow a route of being absorbed from the intestinal tract into the lymphatic vessels in the form of free fatty acids or in the form of monoglycerides. Due to problems such as complete micelle formation and substrate specificity of lipase, the intestinal absorption of omega-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid in fish oil and tuna citrus is not so high.
【０００５】このようなことから、ドコサヘキサエン酸
やエイコサペンタエン酸などのω−３脂肪酸の高吸収性
を考慮した油脂の研究開発が進められてきた。実際、
「新規なトリグリセリド、その製造法、食餌療法及び治
療法への使用並びにそれを含む組成物（特開昭５９−１
９０９４８号公報）」、「合成油脂ならびにこれを含有
する脂肪乳剤輸液および経腸栄養剤（特開昭６３−２９
７３４２号公報）」、「高度不飽和脂肪酸含有トリグリ
セリドを含む油脂の製造方法（特開平０８−２１４８９
１号公報）」などに示されているように、中鎖脂肪酸と
リノール酸などのω−６脂肪酸あるいは中鎖脂肪酸とリ
ノレン酸、ドコサヘキサエン酸やエイコサペンタエン酸
などのω−３脂肪酸をトリグリセリド中に結合する油脂
の開発が進み、その吸収性が優れることなどから、実用
化が待たれる状況になりつつある。そして、これを契機
に、脂肪酸単体から、いわゆる構造脂質としての物理化
学的特性や機能性研究に注目が集まり、現在盛んにその
研究が行われている。[0005] Under such circumstances, research and development of oils and fats taking into account the high absorbency of ω-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid have been promoted. In fact,
"New triglycerides, their production, use in dietary and therapeutic methods and compositions containing them (Japanese Patent Application Laid-Open No. 59-1)
No. 90948) "," Synthetic fats and oils and fat emulsion infusions and enteral nutrients containing the same (Japanese Patent Laid-Open No. 63-29)
No. 7342), “A method for producing fats and oils containing triglycerides containing polyunsaturated fatty acids” (JP-A-08-21489).
No. 1 gazette)), medium-chain fatty acids and ω-6 fatty acids such as linoleic acid, or medium-chain fatty acids and ω-3 fatty acids such as linolenic acid, docosahexaenoic acid and eicosapentaenoic acid are contained in triglyceride. The development of oils and fats to be combined has been advanced, and the absorption of the oils and fats is excellent. At the same time, attention has been focused on studies of physicochemical properties and functionalities of fatty acids alone as so-called structural lipids, and such studies are now being actively conducted.
【０００６】従って、本発明の目的は、ドコサヘキサエ
ン酸やエイコサペンタエン酸などのω−３脂肪酸の腸管
吸収率が非常に高く、かつ低カロリーで、安全性も高
く、運動持久力の向上、カロリーの低減、肥満防止、高
脂血症などの生活習慣病の予防または治療、てんかんの
予防または治療、膵炎、膵嚢胞性線維症などの膵リパー
ゼ分泌欠損患者や胆道閉鎖症などの胆汁酸分泌障害患者
の治療または栄養補給などに有用な、ω−３脂肪酸を含
む油脂の摂取物を提供することにある。Accordingly, an object of the present invention is to provide an intestinal absorption rate of ω-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid which is very high, low in calories, high in safety, high in exercise endurance, and low in calories. Reduction, prevention of obesity, prevention or treatment of lifestyle-related diseases such as hyperlipidemia, prevention or treatment of epilepsy, patients with pancreatitis, deficiency of pancreatic lipase secretion such as pancreatitis, cystic fibrosis, and patients with bile acid secretion disorder such as biliary atresia It is an object of the present invention to provide an ingestion of fats and oils containing omega-3 fatty acids, which is useful for treating or nutritional supplementation.
【０００７】[0007]
【課題を解決するための手段】本発明者らは、ドコサヘ
キサエン酸やエイコサペンタエン酸などのω−３脂肪酸
を含む油脂のリパーゼ酵素を用いた構造脂質に関する研
究を以前より行っており、高度不飽和脂肪酸含有トリグ
リセリドを含む油脂の製造方法（特開平０８−２１４８
９１号公報）について特許出願し、実用化を目指してい
るが、その吸収性に関する研究を行っているうちに、ド
コサヘキサエン酸やエイコサペンタエン酸などのω−３
脂肪酸が２位に結合し、かつ中鎖脂肪酸が１、３位に結
合する油脂（本発明に係る油脂）が、マグロ油やイワシ
油などの魚油に比べ、ドコサヘキサエン酸やエイコサペ
ンタエン酸などのω−３脂肪酸の腸管吸収率が非常に高
いことを見出した。しかも、胆汁酸や膵リパーゼの分泌
を抑制した場合においても同様の効果が認められた。Means for Solving the Problems The present inventors have been conducting research on structural lipids using lipase enzymes of oils and fats containing ω-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid, and have found that they have been highly unsaturated. Process for producing fats and oils containing fatty acid-containing triglycerides (Japanese Patent Application Laid-Open No. 08-2148)
No. 91) and applying for a patent, and while conducting research on its absorbency, ω-3 such as docosahexaenoic acid or eicosapentaenoic acid was discovered.
Fats and oils in which a fatty acid is bonded at the 2-position and a medium-chain fatty acid is bonded at the 1- and 3-positions (the fats and oils according to the present invention) are compared with fish oils such as tuna oil and sardine oil such as ω such as docosahexaenoic acid and eicosapentaenoic acid. The intestinal absorption of -3 fatty acids was found to be very high. Moreover, a similar effect was observed when secretion of bile acids and pancreatic lipase was suppressed.
【０００８】また、上記油脂は、魚をはじめとする自然
界の動植物の組成成分と同様にトリグリセリドの形態を
有し、製造に使用するリパーゼ酵素も食品用に汎用され
ているものを用いることができ、１、３位に結合する中
鎖脂肪酸はココナッツオイルなどに多く含まれるカプロ
ン酸、カプリル酸、カプリン酸、ラウリル酸などの脂肪
酸で、そのトリグリセリド体（ＭＣＴ）は術後のカロリ
ー補給に汎用されているものであることから、上記油脂
は、安全性の非常に高いものである。The fats and oils have the form of triglycerides, similar to the components of animals and plants in nature, such as fish, and lipase enzymes used in production can be those commonly used for foods. The medium-chain fatty acids linked to the 1,3-position are fatty acids such as caproic acid, caprylic acid, capric acid, and lauric acid that are often contained in coconut oil and the like, and their triglyceride form (MCT) is widely used for postoperative caloric supplementation. Therefore, the fats and oils are very safe.
【０００９】さらに、本発明者らは、上記油脂の生理作
用について鋭意研究を進めた結果、上記油脂は、意外に
も、マグロ油やイワシ油などの魚油に比べ、低カロリー
であり、肥満防止作用のあること、運動持久力を向上さ
せるなどの運動能力を高めること、高脂血症などの脂質
代謝改善作用が強力であることを見出し、さらに詳細な
薬効薬理試験を実施した結果、抗てんかん作用や膵炎、
膵嚢胞性線維症などの膵リパーゼ分泌欠揖や胆道閉鎖症
などの胆汁酸分泌障害のモデル動物においても症状の改
善を示すことを見出した。Furthermore, the present inventors have made intensive studies on the physiological action of the above-mentioned fats and oils. As a result, the above-mentioned fats and fats are unexpectedly low in calories compared to fish oils such as tuna oil and sardine oil. It has been found that it has an activity, enhances exercise ability such as improving exercise endurance, and has a strong effect of improving lipid metabolism such as hyperlipidemia. Action or pancreatitis,
We also found that animal models of pancreatic lipase secretion deficiency such as cystic fibrosis and bile acid secretion disorders such as biliary atresia show improvement in symptoms.
【００１０】本発明は、上述の研究に基づいてなされた
もので、ω−３脂肪酸が２位に結合し、かつ中鎖脂肪酸
が１、３位に結合する油脂を、哺乳動物が１日３０ｍｇ
以上を摂取することを可能とする摂取物を提供するもの
である。尚、本明細書において、油脂とトリグリセリド
とは、同義語として使用する。[0010] The present invention has been made based on the above-mentioned research, and a mammal comprising 30 mg / day of an oil or fat in which an ω-3 fatty acid binds to the 2-position and a medium-chain fatty acid binds to the 1-3 position.
It is intended to provide an ingested food that allows the above to be ingested. In this specification, fats and oils and triglycerides are used as synonyms.
【００１１】[0011]
【発明の実施の形態】以下、本発明の摂取物について詳
述する。本発明の摂取物である油脂（トリグリセリド）
の２位に結合したω−３脂肪酸としては、ドコサヘキサ
エン酸、エイコサペンタエン酸の他に、リノール酸、ド
コサペンタエン酸、オクタデカテトラエン酸などが挙げ
られるが、ドコサヘキサエン酸、エイコサペンタエン酸
が好ましく、ドコサヘキサエン酸が特に好ましい。BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the ingested food of the present invention will be described in detail. Fats and oils (triglycerides) which are the ingested food of the present invention
Examples of the ω-3 fatty acid bonded to the 2-position include docosahexaenoic acid and eicosapentaenoic acid, as well as linoleic acid, docosapentaenoic acid, and octadecatetraenoic acid, with docosahexaenoic acid and eicosapentaenoic acid being preferred. And docosahexaenoic acid are particularly preferred.
【００１２】また、本発明の摂取物である油脂（トリグ
リセリド）の１、３位に結合した中鎖脂肪酸としては、
カプロン酸、カプリル酸、カプリン酸、ラウリル酸など
の炭素原子数６〜１２の直鎖もしくは分岐の飽和もしく
は不飽和脂肪酸が挙げられ、中でもカプリル酸が好まし
い。The medium-chain fatty acids linked to the 1,3-positions of the fats and oils (triglycerides) to be consumed according to the present invention include:
Examples thereof include straight-chain or branched saturated or unsaturated fatty acids having 6 to 12 carbon atoms, such as caproic acid, caprylic acid, capric acid, and lauric acid, with caprylic acid being preferred.
【００１３】本発明の摂取物は、上記ω−３脂肪酸が２
位に結合し、かつ上記中鎖脂肪酸が１、３位に結合する
油脂を含有するものであり、例えば、カプセル剤、錠剤
型、または、粉乳などの散剤型はもとより、清涼飲料水
やスポーツドリンクなどの各種飲料、チューインガム、
菓子類、チルド食品、冷凍食品やレトルト食品などの人
間用摂取物、ドックフードやキャットフード等の動物用
摂取物の形態を挙げることができる。The food of the present invention is characterized in that
And the above-mentioned medium-chain fatty acid contains fats and oils which bind to the 1- and 3-positions. Examples thereof include powders such as capsules, tablets, and powdered milk, as well as soft drinks and sports drinks. Beverages, chewing gum, etc.
Examples include forms of human consumption such as confectionery, chilled food, frozen food and retort food, and animal consumption such as dock food and cat food.
【００１４】本発明の摂取物は、摂取者（哺乳動物）が
上記油脂を１日３０ｍｇ以上、好ましくは１日６０〜１
０００ｍｇを摂取できるように、上記油脂を含有してい
る必要がある。上記油脂の１日の摂取量が３０ｍｇ未満
であると、ω−３脂肪酸の高吸収率の効果が顕著にみら
れない。The ingested food of the present invention is prepared so that the ingestor (mammal) can use the oil or fat at a dose of 30 mg or more per day, preferably 60 to 1 per day.
It is necessary to contain the above fats and oils so that 000 mg can be taken. When the daily intake of the fat or oil is less than 30 mg, the effect of the high absorption rate of the ω-3 fatty acid is not remarkably observed.
【００１５】本発明の摂取物が１日に何回かに分けて摂
取される形態のものである場合には、上記油脂の１日の
摂取量の合計量が３０ｍｇ以上となるように、本発明の
摂取物に上記油脂を含有させればよい。例えば、本発明
の摂取物を朝、昼、夕と１日に３回に分けて摂取する場
合には、１回あたり上記油脂を最低１０ｍｇ以上を摂取
できるように含有させればよく、また朝、昼、夕、晩と
４回に分けて摂取する場合には、１回あたり最低７．５
ｍｇ以上を摂取できるように含有させればよい。このよ
うに、本発明の摂取物に含有させる上記油脂の量は、本
発明の摂取物の１日あたりの摂取回数および１回あたり
の本発明の摂取物の摂取量によって調整することができ
る。When the ingested food of the present invention is in the form of being ingested several times a day, the fat or oil should be so taken that the total daily intake of the fat or oil is 30 mg or more. What is necessary is just to make the ingestion of this invention contain the said fats and oils. For example, when the ingestion of the present invention is taken three times a day in the morning, afternoon, evening and evening, the above fats and oils may be contained so that at least 10 mg or more can be taken each time. , Four times a day, evening, evening, at least 7.5 per dose
What is necessary is just to contain so that mg or more may be taken. As described above, the amount of the fat or oil to be contained in the ingestion of the present invention can be adjusted by the number of times of ingestion of the ingestion of the present invention per day and the amount of ingestion of the ingestion of the present invention per one time.
【００１６】上記油脂を摂取物に含有させる方法として
は、上記形態の摂取物を製造する何れかの工程において
上記油脂を添加すればよく、また上記油脂は、他の油脂
を含む混合油脂として添加してもよい。As a method of incorporating the above fats and oils into the ingested food, the above fats and oils may be added in any step of producing the above ingested foods, and the above fats and oils may be added as a mixed fat and oil containing other fats and oils. May be.
【００１７】本発明の摂取物は、運動持久力の向上、摂
取カロリーの低減、肥満防止、高脂血症などの生活習慣
病の予防または治療、てんかんの予防または治療、膵
炎、膵嚢胞性線維症などの膵リパーゼ分泌欠損患者や胆
道閉鎖症などの胆汁酸分泌障害患者の治療または栄養補
給などを目的として摂取することができるものである。The ingestion of the present invention can be used to improve exercise endurance, reduce calorie intake, prevent obesity, prevent or treat lifestyle-related diseases such as hyperlipidemia, prevent or treat epilepsy, pancreatitis, cystic fibrosis It can be taken for the purpose of treatment or nutritional supplementation of patients with pancreatic lipase secretion deficiency such as sclerosis or bile acid secretion disorder such as biliary atresia.
【００１８】[0018]
【実施例】以下、実施例により本発明の効果を具体的に
説明する。但し、本発明は、これらの実施例に限定され
ない。EXAMPLES The effects of the present invention will be specifically described below with reference to examples. However, the present invention is not limited to these examples.
【００１９】実施例１ 〔ドコサヘキサエン酸（ＤＨＡ）の腸管吸収性試験〕 （試験内容）膵リパーゼ分泌欠損や胆汁酸分泌障害にお
ける使用を想定して、ＤＨＡが２位に結合し、かつカプ
リル酸が１、３位に結合するトリグリセリド（ＤＭＣ
Ｔ）含有油脂のラットにおけるＤＨＡの腸管吸収性を、
胸管リンパカニュレーション手法と膵リパーゼおよび胆
汁酸のそれぞれの分泌管をクリップで止める手法とを組
み合わせて実施した。また、対照として、マグロ油を用
いた。Example 1 [Intestinal Absorbency Test of Docosahexaenoic Acid (DHA)] (Content of test) Assuming use in pancreatic lipase secretion deficiency or bile acid secretion disorder, DHA binds to position 2 and caprylic acid Triglycerides (DMC
T) The intestinal absorptivity of DHA containing fats and oils in rats
The thoracic duct lymph cannulation technique was combined with the technique of clipping the respective secretory tracts of pancreatic lipase and bile acid. Tuna oil was used as a control.
【００２０】（試験方法） ＤＭＣＴ含有油脂の調製 ＤＭＣＴ含有油脂は、高度不飽和脂肪酸含有トリグリセ
リドを含む油脂の製造方法（特開平０８−２１４８９１
号公報に記載の実施例３）に準じて調製した。このＤＭ
ＣＴ含有油脂を分析した結果、全トリグリセリド量は９
９．５質量％で、ＤＭＣＴは３０．７質量％であった。
このＤＭＣＴ含有油脂の脂肪酸組成および対照のマグロ
油の脂肪酸組成をそれぞれ下記表１に示した。(Test method) Preparation of DMCT-containing fats and oils DMCT-containing fats and oils were prepared by a method for producing fats and oils containing triglycerides containing highly unsaturated fatty acids (Japanese Patent Laid-Open No. 08-214891).
The preparation was carried out according to Example 3) described in JP-A No. This DM
As a result of analyzing the CT-containing fats and oils, the total triglyceride amount was 9
At 9.5% by weight, the DMCT was 30.7% by weight.
The fatty acid composition of the DMCT-containing fat and oil and the fatty acid composition of the control tuna oil are shown in Table 1 below.
【００２１】[0021]
【表１】 [Table 1]
【００２２】実験動物 日本エスエルシー（株）より購入したＳＤ雄性ラット
（平均体重３８４±９ｇ、１１週齢前後）を使用した。
馴化期間は一週間とした。飼料はＦ−１固形飼料（船橋
農場製）を自由摂取させた。Experimental Animals SD male rats (average body weight: 384 ± 9 g, around 11 weeks of age) purchased from Japan SLC, Inc. were used.
The acclimatization period was one week. The feed was allowed to freely ingest F-1 solid feed (Funabashi Farm).
【００２３】動物モデルの作製（胸部リンパ管カニュ
レーション） ペントバルビタール麻酔下、腹部から左背部にかけて剃
毛後、ラットの剣状突起より約２ｃｍ下方を体軸に対し
て垂直に両脇までハサミで切開し、脂肪や結合組織をか
きわけ、動脈に縫合糸（ブレード絹製縫合糸Ｎ０．３，
夏目製作所）を架けて腹大動脈裏側にある胸部リンパ管
を露出させた。縫合糸でリンパ管の下流部（横隔膜側）
を結紮し、リンパ管の結紮部位から約５ｍｍ上流側のリ
ンパ管にも同様の縫合糸をくぐらせ、緩く結んでおい
た。下流部を結紮することで怒張したリンパ管にハサミ
で切り込みを入れ、リンパ管内にビニールチューブ（SV
35 I.D.;0.5mm O.D.;0.9mm, 夏目製作所）を挿入し、あ
らかじめくぐらせておいた縫合糸で固定した。併せて，
膵リバーゼおよび胆汁酸のそれぞれの分泌管をクリップ
で止めた。Preparation of animal model (thoracic lymph vessel cannulation) Under pentobarbital anesthesia, shaving was performed from the abdomen to the left back, and then approximately 2 cm below the xiphoid process of the rat, with scissors perpendicular to the body axis to both sides. An incision is made, the fat and connective tissue are separated, and a suture (blade silk suture N0.3,
(Natsume Seisakusho) to expose the thoracic lymphatic vessels behind the abdominal aorta. Suture downstream of lymphatic vessels (diaphragm side)
Was ligated, and a similar suture was passed through the lymphatic vessel approximately 5 mm upstream from the ligated site of the lymphatic vessel and loosely tied. Ligation of the downstream part is performed by cutting with scissors into the lymphatic vessel that has become angry, and a vinyl tube (SV
35 ID; 0.5 mm OD; 0.9 mm, Natsume Seisakusho) was inserted, and fixed with a suture thread previously passed through. together,
The respective secretory tracts of pancreatic rivase and bile acids were clipped.
【００２４】結紮部位は瞬間接着剤を滴下して結紮を補
助した。次に先端から３ｃｍの位置に印を付けておいた
ポリエチレンチューブ（SP55 I.D.;0.8mm O.D.;1.2mm,
夏目製作所）を血管を避けて印の部分まで胃底大弯部に
挿入した。挿入したチューブを胃壁側に指で寄せた後、
挿入付近とチューブ先端付近の２箇所を縫合糸で結び、
瞬間接着剤を滴下して胃に固定した。At the ligated site, a lump was applied by dropping an instant adhesive to assist the ligature. Next, a polyethylene tube (SP55 ID; 0.8 mm OD; 1.2 mm,
(Natsume Seisakusho) was inserted into the fundus fundus of the fundus to avoid the blood vessels. After moving the inserted tube to the stomach wall with your finger,
Connect two places near the insertion and near the tip of the tube with a suture,
The instant adhesive was dropped and fixed on the stomach.
【００２５】その後、各々のチューブを腹壁ならびに表
皮を貫通させて体外へ出し、臓器を腹腔内に戻した。そ
の後、切開した部分の筋層を縫合糸で単純連続縫合し、
続いて表皮を縫合糸で単純連続縫合した。手術終了後の
動物は拘束ケージ（ＫＮ式ポールマンケージ１型，夏目
製作所）に固定した。回復後、拘束ケージを室内温度２
５±２℃、湿度５５±１０％に調整したアイソラック
（ISK-9-3-B KAIRYOGATA, OSHITARI）に入れ、動物には
インフュージョンポンプ（PHD2000, HARVERD）に装着し
たシリンジ（５０ｍＬ，テルモ）から胃チューブを介し
て２．５％グルコース生理食塩水溶液を３ｍＬ／ｈの流
速で投与した。また、給水瓶にも２．５％グルコース生
理食塩水溶液を入れ自由摂取させた。この状態で一晩管
理し、翌朝からリンパ液採取を開始した。また、手術か
ら実験終了までは絶食下で行った。Thereafter, each tube was penetrated through the abdominal wall and the epidermis and was taken out of the body, and the organ was returned into the abdominal cavity. After that, the muscle layer of the incised part is simply and continuously sutured with a suture,
Subsequently, the epidermis was simply and continuously sutured with a suture. After the operation, the animals were fixed in a restraining cage (KN-type Paulman cage type 1, Natsume Seisakusho). After recovery, keep the restraint cage at room temperature 2
Syringe (50 mL, Terumo) attached to an infusion pump (PHD2000, HARVERD) for animals placed in Isorac (ISK-9-3-B KAIRYOGATA, OSHITARI) adjusted to 5 ± 2 ° C and humidity 55 ± 10% Was administered via a gastric tube at a flow rate of 3 mL / h of a 2.5% glucose physiological saline solution. In addition, a 2.5% glucose physiological saline solution was also placed in the water bottle to allow free intake. In this state, management was performed overnight, and lymph fluid collection was started the next morning. In addition, the operation was performed under fasting conditions from the operation to the end of the experiment.
【００２６】投与方法 ＤＭＣＴ含有油脂およびマグロ油を５％アラビアゴム水
溶液に懸濁調製後、３ｍＬを胃チューブを介し胃内へ投
与した。ＤＭＣＴ含有油脂およびマグロ油の投与量は、
それぞれラット体重１ｋｇあたり１００ｍｇとした。Administration Method DMCT-containing fats and oils and tuna oil were suspended and prepared in a 5% aqueous solution of gum arabic, and then 3 mL was administered into the stomach via a gastric tube. The dose of DMCT-containing fats and oils and tuna oil is
Each dose was 100 mg / kg of rat body weight.
【００２７】（試験結果）本モデル系でのＤＨＡの吸収
量は、ＤＭＣＴ含有油脂を投与した場合が、マグロ油を
投与した場合よりも顕著に高かった。図１に示すよう
に、吸収のピークである投与後３時間目のＤＨＡ平均吸
収率は、ＤＭＣＴ含有油脂の場合が２３．３％で、マグ
ロ油の場合が６．６％であり、ＤＭＣＴ含有油脂の場合
がマグロ油の場合の約３．５倍であった。また、エイコ
サペンタエン酸などの他の脂肪酸においても同様の結果
が得られた。(Test Results) The absorption amount of DHA in the present model system was significantly higher when DMCT-containing fats and oils were administered than when tuna oil was administered. As shown in FIG. 1, the DHA average absorption at 3 hours after administration, which is the peak of absorption, was 23.3% for DMCT-containing fats and oils, 6.6% for tuna oil, and The case of fats and oils was about 3.5 times that of tuna oil. Similar results were obtained with other fatty acids such as eicosapentaenoic acid.
【００２８】以上の結果より、膵嚢胞性線維症などの膵
リパーゼ分泌欠損患者や胆汁酸分泌障害患者の治療また
は栄養補給の目的で本発明のＤＭＣＴ含有油脂が有用で
あることが示された。尚、本試験では、ＤＭＣＴを３
０．７質量％含有するＤＭＣＴ含有油脂のラットへの投
与量が、ラット体重１ｋｇあたり１００ｍｇであるか
ら、ＤＭＣＴのラットへの投与量は、ラット体重１ｋｇ
あたり約３０ｍｇであり、この量で十分なＤＨＡの高吸
収性が示されている。一般に、ラットおよびマウスとヒ
トとを比較した場合、ラットおよびマウスはヒトに比べ
脂溶性成分の感受性が約６０倍弱いと考えられており、
今回のラット体重１ｋｇあたり約３０ｍｇのＤＭＣＴの
投与量は、ヒト（６０ｋｇ体重）に換算するとほぼ同用
量となる。従って、ヒトの場合は、ＤＭＣＴを１日３０
ｍｇ以上を摂取すればよいことになる。The above results indicate that the DMCT-containing fats and oils of the present invention are useful for the treatment or nutritional supplementation of patients with pancreatic lipase secretion deficiency such as cystic fibrosis and bile acid secretion disorder. In this test, DMCT was 3
Since the dose of the DMCT-containing fat and oil containing 0.7% by mass to rats is 100 mg / kg of rat body weight, the dose of DMCT to rats is 1 kg of rat body weight.
Approximately 30 mg per DHA, indicating that the amount of DHA is sufficiently high. Generally, when rats and mice are compared with humans, it is considered that rats and mice are about 60 times less sensitive to fat-soluble components than humans,
This dose of about 30 mg of DMCT per 1 kg of rat body weight is almost the same when converted to human (60 kg body weight). Therefore, in the case of humans, DMCT should be administered for 30 days a day.
It would be good to take more than mg.
【００２９】実施例２ 〔体重増加抑制試験〕 （試験内容）ＤＭＣＴ含有油脂のラットにおける体重増
加抑制性を確認した。対照として、マグロ油を用いた。 （試験方法）ＤＭＣＴ含有油脂は、実施例１で調製した
もの（ＤＭＣＴ３０．７質量％含有油脂）を使用した。
ラットは、日本チヤールスリバー（株）より購入したＳ
Ｄ雌性ラット（平均体重１０１±１０ｇ、４週齢）を使
用した。馴化期間は１週間とした。飼料は、下記表２に
示した配合表に従い、試験群にはＤＭＣＴ含有油脂を飼
料中に３．０％、対照群にはマグロ油を飼料中に３．０
％それぞれ配合し作製した。試験は、ラット各群８匹に
下記表２の飼料を６週間摂取させ、体重の増加量を測定
した。Example 2 [Test for inhibiting weight gain] (Content of test) The inhibitory effect of DMCT-containing fats and oils on weight gain in rats was confirmed. Tuna oil was used as a control. (Test method) As the DMCT-containing fat, the one prepared in Example 1 (DMCT containing 30.7% by mass-containing fat) was used.
Rats were S purchased from Nippon Charles River Co., Ltd.
D female rats (average body weight 101 ± 10 g, 4 weeks old) were used. The acclimatization period was one week. According to the formulation shown in Table 2 below, the feed was 3.0% DMCT-containing fat and oil in the test group and 3.0% tuna oil in the control group.
%. In the test, 8 rats in each group were fed the feed shown in Table 2 for 6 weeks, and the amount of weight gain was measured.
【００３０】[0030]
【表２】 [Table 2]
【００３１】（試験結果）飼料摂取開始４週後および６
週後の体重を試験群と対照群で比較した結果、下記表３
に示す通り、ＤＭＣＴ含有油脂を摂取した試験群が、対
照群に比べて有意に体重増加を抑制することが明らかに
なった。また、試験期間内における両群の飼料摂取量に
統計的な差は認められなかった。(Test results) 4 weeks after the start of feed intake and 6
As a result of comparing the body weight after a week between the test group and the control group, the following Table 3 was used.
As shown in the figure, it was revealed that the test group in which DMCT-containing fats and oils were ingested significantly suppressed weight gain as compared with the control group. No statistical difference was observed in the feed intake between the two groups during the test period.
【００３２】[0032]
【表３】 [Table 3]
【００３３】実施例３ 〔運動持久力試験〕 （試験内容）ＤＭＣＴ含有油脂のマウスにおける運動持
久力を確認した。対照として、マグロ油を用いた。 （試験方法）ＤＭＣＴ含有油脂は、実施例１で調製した
もの（ＤＭＣＴ３０．７質量％含有油脂）を使用した。
マウスは、日本エスエルシー（株）より購入したｄｄＹ
雄性マウス（平均体重２３．２±２．１ｇ、５週齢）を
使用した。馴化期間は１週間とした。飼料は、下記表４
に示した配合表に従い、ＤＭＣＴ試験群にはＤＭＣＴ含
有油脂を飼料中に７．０％、マグロ油試験群にはマグロ
油を飼料中に７．０％それぞれ配合し作製した。試験
は、長さ１ｍ×幅５０ｃｍ×深さ４０ｃｍの水槽（水温
３３℃）にポンプを用いて緩やかな水流を発生させ、そ
の中に各群１０匹のマウスを遊泳させ、持久力を失うま
での泳ぐ時間を測定した。測定は、マウス各群１０匹に
下記表４の飼料を６週間摂取させ、飼料摂取前および飼
料摂取開始後２週毎に実施した。Example 3 [Exercise endurance test] (Content of test) Exercise endurance of mice containing DMCT-containing fats and oils was confirmed. Tuna oil was used as a control. (Test method) As the DMCT-containing fat, the one prepared in Example 1 (DMCT containing 30.7% by mass-containing fat) was used.
The mouse was ddY purchased from Japan SLC, Inc.
Male mice (average body weight 23.2 ± 2.1 g, 5 weeks old) were used. The acclimatization period was one week. The feed is shown in Table 4 below
According to the formulation shown in Table 2, the DMCT test group was prepared by mixing the DMCT-containing oil and fat in the feed at 7.0%, and the tuna oil test group was prepared by mixing 7.0% of tuna oil in the feed. In the test, a gentle water flow was generated using a pump in a water tank (water temperature: 33 ° C.) having a length of 1 m, a width of 50 cm and a depth of 40 cm, and 10 mice of each group were allowed to swim in the bath until the endurance was lost. The swim time was measured. The measurement was performed by ingesting the feed shown in Table 4 below for 6 weeks for each group of 10 mice for 6 weeks, and before the feed intake and every two weeks after the start of the feed intake.
【００３４】[0034]
【表４】 [Table 4]
【００３５】（試験結果）下記表５に示す通り、飼料摂
取開始４週後には、ＤＭＣＴ試験群が、対照群に比べ有
意に運動持久力が向上し、飼料摂取開始６週後には、Ｄ
ＭＣＴ試験群が、マグロ油試験群と対照群の両群に比べ
有意に運動持久力が向上した。また、マグロ油試験群
は、飼料摂取開始６週後には対照群に比べ有意に運動持
久力が向上した。(Test Results) As shown in Table 5 below, 4 weeks after the start of feed intake, the DMCT test group significantly improved exercise endurance compared with the control group, and 6 weeks after the start of feed intake, D
The MCT test group had significantly improved exercise endurance compared to both the tuna oil test group and the control group. In the tuna oil test group, the exercise endurance was significantly improved 6 weeks after the start of feed intake as compared with the control group.
【００３６】[0036]
【表５】 [Table 5]
【００３７】実施例４ 〔脂質代謝改善作用〕 （試験内容）ＤＭＣＴ含有油脂のラットにおける脂質代
謝改善作用を確認した。対照として、マグロ油を用い
た。 （試験方法）ＤＭＣＴ含有油脂は、実施例１で調製した
もの（ＤＭＣＴ３０．７質量％含有油脂）を使用した。
ラットは、日本チャールスリバー（株）より購入したWi
star雄性ラット（平均体重９８±１１ｇ、４週齢）を使
用した。馴化期間は１週間とした。飼料は、魚粉抜きＦ
−１飼料（船橋農場製）を基本にコレステロールを１％
およびコール酸を１％添加したコレステロール添加飼料
を作製し、試験に用いた。馴化期間中は魚粉抜きＦ−１
飼料で飼育した。群構成は下記表６に示した。試験開始
時より、コレステロール添加飼料を各群に給餌し、同時
にＤＭＣＴ含有油脂またはマグロ油を規定量、５％アラ
ビアゴム溶液に懸濁し、ゾンデを用いて１日１回強制経
口投与を実施した。対照群は５％アラビアゴム溶液のみ
を投与した。試験開始４週後に腹部大動脈より採血を行
い、血清分離後、総コレステロール値の測定を行った。Example 4 [Effect of improving lipid metabolism] (Content of test) The effect of DMCT-containing fats and oils on improving lipid metabolism in rats was confirmed. Tuna oil was used as a control. (Test method) The DMCT-containing fats and oils prepared in Example 1 (DMCT containing 30.7% by mass fats and oils) were used.
Rats are Wi-Fi purchased from Charles River Japan
Star male rats (average body weight 98 ± 11 g, 4 weeks old) were used. The acclimatization period was one week. For feed, remove fish meal F
-1 1% cholesterol based on feed (Funabashi Farm)
And a cholesterol-supplemented feed supplemented with 1% of cholic acid was prepared and used for the test. F-1 without fish meal during acclimatization period
They were kept on feed. The group constitution is shown in Table 6 below. From the start of the test, a cholesterol-added feed was fed to each group, and at the same time, a prescribed amount of a DMCT-containing fat or oil or tuna oil was suspended in a 5% gum arabic solution, and gavage administration was performed once a day using a sonde. The control group received only a 5% gum arabic solution. Four weeks after the start of the test, blood was collected from the abdominal aorta, the serum was separated, and the total cholesterol level was measured.
【００３８】[0038]
【表６】 [Table 6]
【００３９】（試験結果）図２に示すように、ＤＭＣＴ
含有油脂１０００群が、対照群に比べ有意に血清中の総
コレステロール値の上昇を抑制した。また、ＤＭＣＴ含
有油脂３００群および１０００群と、マグロ油３００群
および１０００群とを比較した場合、ＤＭＣＴ含有油脂
群の方が、マグロ油群に比べ有意に血清中の総コレステ
ロール値の上昇を抑制していることが認められた。(Test Results) As shown in FIG.
The 1000 fats and oils group significantly suppressed the increase in the total cholesterol level in serum as compared with the control group. In addition, when the DMCT-containing fats and oils 300 and 1000 groups were compared with the tuna oils 300 and 1000 groups, the DMCT-containing fats and oils group significantly suppressed the increase of the total cholesterol level in serum as compared with the tuna oil group. It was recognized that it was.
【００４０】実施例５ 〔抗てんかん作用〕 （試験内容）ＤＭＣＴ含有油脂のラットにおける電撃痙
攣に対する作用を確認した。対照として、マグロ油を用
いた。 （試験方法）ＤＭＣＴ含有油脂は、実施例１で調製した
もの（ＤＭＣＴ３０．７質量％含有油脂）を使用した。
ラットは、日本チャールスリバー（株）より購入したWi
star雄性ラット（平均体重１１０±１４ｇ、５週齢）を
使用した。馴化期間は１週間とした。飼料は、魚粉抜き
Ｆ−１飼料（船橋農場製）を用いた。馴化期間中も魚粉
抜きＦ−１飼料で飼育した。群構成は下記表７に示し
た。試験開始時より、ＤＭＣＴ含有油脂またはマグロ油
を規定量、５％アラビアゴム溶液に懸濁し、ゾンデを用
いて１日１回強制経口投与を実施した。対照群は５％ア
ラビアゴム溶液のみを投与した。試験開始４週後に、電
撃痙攣による手法で硬直性痙攣、間代性痙攣および昏睡
の持続時間を比較した。Example 5 [Anti-epileptic effect] (Content of test) The effect of DMCT-containing fats and oils on electroconvulsive convulsions in rats was confirmed. Tuna oil was used as a control. (Test method) As the DMCT-containing fat, the one prepared in Example 1 (DMCT containing 30.7% by mass-containing fat) was used.
Rats are Wi-Fi purchased from Charles River Japan
Star male rats (average body weight 110 ± 14 g, 5 weeks old) were used. The acclimatization period was one week. As the feed, a fish meal-free F-1 feed (manufactured by Funabashi Farm) was used. During the habituation period, the animals were bred on a fish meal-free F-1 diet. The group constitution is shown in Table 7 below. From the start of the test, a prescribed amount of DMCT-containing fat or oil or tuna oil was suspended in a 5% gum arabic solution, and gavage administration was performed once a day using a sonde. The control group received only a 5% gum arabic solution. Four weeks after the start of the test, the duration of rigid convulsions, clonic convulsions and coma were compared by the method of electroconvulsive seizures.
【００４１】[0041]
【表７】 [Table 7]
【００４２】（試験結果）図３に示すように、ＤＭＣＴ
含有油脂１０００群とマグロ油１０００群が、対照群に
比べ硬直性痙攣時間と昏睡時間の短縮が認められた。ま
た、ＤＭＣＴ含有油脂１０００群とマグロ油１０００群
とを比較した場合、ＤＭＣＴ含有油脂１０００群の方
が、硬直性痙攣時間を短縮することが明らかになった。
間代性痙攣においては、各群間に差は認められなかっ
た。以上の結果より、抗てんかん作用の指標となる硬直
性痙攣において、ＤＭＣＴは、マグロ油に比べ有効性が
高いと判断された。(Test Results) As shown in FIG.
The stiff convulsion time and the coma time were shortened in the oil-containing fat 1000 group and the tuna oil 1000 group as compared with the control group. In addition, when the 1000 groups of DMCT-containing fats and oils were compared with the 1000 groups of tuna oils, it became clear that the 1000 groups of DMCT-containing fats and oils shortened the stiffness convulsion time.
In clonic convulsions, no difference was observed between the groups. From the above results, it was determined that DMCT was more effective than tuna oil in stiff convulsions, which is an index of antiepileptic action.
【００４３】実施例６ 〔ＤＭＣＴ含有油脂を配合した軟カプセル剤〕下記表８
に示す処方の軟カプセル剤を常法により調製した。％は
質量％を表す。Example 6 [Soft capsule containing DMCT-containing fats and oils] Table 8 below
Soft capsules having the formulation shown in Table 1 were prepared by a conventional method. % Represents mass%.
【００４４】[0044]
【表８】 [Table 8]
【００４５】実施例７ 〔ＤＭＣＴ含有油脂を配合したチューインガム〕下記表
９に示す処方のチューインガムを常法により調製した。Example 7 [Chewing gum containing DMCT-containing fats and oils] A chewing gum having the formulation shown in Table 9 below was prepared by a conventional method.
【００４６】[0046]
【表９】 [Table 9]
【００４７】実施例８ 〔ＤＭＣＴ含有油脂を配合した飲料〕下記表１０に示す
処方の飲料を常法により調製した。Example 8 [Beverage containing DMCT-containing fats and oils] A beverage having the formulation shown in Table 10 below was prepared by a conventional method.
【００４８】[0048]
【表１０】 [Table 10]
【００４９】実施例９ 〔ＤＭＣＴ含有油脂を配合したビスケット〕下記表１１
に示す処方のビスケットを常法により調製した。Example 9 [Biscuit containing DMCT-containing fats and oils] Table 11 below
A biscuit having the formula shown in Table 1 was prepared by a conventional method.
【００５０】[0050]
【表１１】 [Table 11]
【００５１】実施例１０ 〔ＤＭＣＴ含有油脂を配合したペットフード〕下記表１
２に示す処方のペットフードを常法により調製した。％
は質量％を表す。Example 10 [Pet food containing DMCT-containing fats and oils] Table 1 below
A pet food having the formulation shown in No. 2 was prepared by a conventional method. %
Represents mass%.
【００５２】[0052]
【表１２】 [Table 12]
【００５３】[0053]
【発明の効果】本発明のω−３脂肪酸を含む油脂の摂取
物は、ドコサヘキサエン酸やエイコサペンタエン酸など
のω−３脂肪酸の腸管吸収率が非常に高く、かつ低カロ
リーで、安全性も高く、運動持久力を高めるためのスポ
ーツ食品、肥満防止の低カロリー食品、高脂血症などの
生活習慣病を予防する食品、抗てんかん作用を有する食
品、膵炎、膵嚢胞性線維症などの膵リパーゼ分泌欠損患
者や胆道閉鎖症などの胆汁酸分泌障害患者の治療または
栄養補給を目的とする食品または医療用組成物に応用す
ることができ、幅広く国民の健康に寄与できる。The ingested fats and oils containing ω-3 fatty acids of the present invention have a very high intestinal absorption rate of ω-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid, are low in calories, and have high safety. , Sports foods to increase exercise endurance, low calorie foods to prevent obesity, foods to prevent lifestyle-related diseases such as hyperlipidemia, foods with antiepileptic activity, pancreatitis, pancreatic lipase such as cystic fibrosis It can be applied to foods or medical compositions intended for the treatment or nutritional supplementation of patients with secretion deficiency and bile acid secretion disorders such as biliary atresia, and can contribute to the health of the general public.
【図１】図１は、実施例１のＤＭＣＴ含有油脂の腸管吸
収性試験におけるＤＨＡ平均吸収率の経時変化を示すグ
ラフである。FIG. 1 is a graph showing the change over time in the average absorption rate of DHA in an intestinal absorption test of a DMCT-containing oil and fat of Example 1.
【図２】図２は、実施例４のＤＭＣＴ含有油脂の脂質代
謝改善作用試験における血清中の総コレステロール値の
測定結果を示すグラフである。FIG. 2 is a graph showing the results of measuring the total cholesterol level in serum in a lipid metabolism improving effect test of the DMCT-containing fats and oils of Example 4.
【図３】図３は、実施例５のＤＭＣＴ含有油脂の抗てん
かん作用試験における硬直性痙攣時間、間代性痙攣時間
および昏睡時間の測定結果を示すグラフである。FIG. 3 is a graph showing the results of measurement of stiff convulsion time, clonic convulsion time, and coma time in the antiepileptic action test of the DMCT-containing oil and fat of Example 5.
フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｋ 31/232 Ａ６１Ｐ 1/16 ４Ｂ０３２ Ａ６１Ｐ 1/16 1/18 ４Ｃ２０６ 1/18 3/04 ４Ｈ０５９ 3/04 3/06 3/06 25/08 25/08 Ａ２１Ｄ 13/08 // Ａ２１Ｄ 13/08 Ａ２３Ｇ 3/30 Ａ２３Ｇ 3/30 Ａ２３Ｌ 2/38 Ｚ Ａ２３Ｌ 2/52 Ａ２３Ｄ 9/00 ５１４ 2/38 ５１６ ５１８ Ａ２３Ｌ 2/00 Ｆ (72)発明者 丸山 一輝 栃木県宇都宮市清原工業団地８−１ マル ハ株式会社化成食品事業部内 Ｆターム(参考） 2B150 AA06 AB03 AB20 DA54 DA55 DA56 DA57 4B014 GB13 GG14 GK12 4B017 LC03 LK10 LL09 4B018 LB01 LB08 MD11 MD14 ME14 4B026 DC05 DG20 DH10 DP10 4B032 DB21 DK18 DL20 4C206 AA01 AA02 DB09 DB48 MA01 MA04 MA72 NA14 ZA06 ZA66 ZA70 ZA75 ZC33 4H059 BA33 BB02 BB05 BB06 Continued on the front page (51) Int.Cl. 7 Identification code FI Theme coat II (Reference) A61K 31/232 A61P 1/16 4B032 A61P 1/16 1/18 4C206 1/18 3/04 4H059 3/04 3/06 3/06 25/08 25/08 A21D 13/08 // A21D 13/08 A23G 3/30 A23G 3/30 A23L 2/38 Z A23L 2/52 A23D 9/00 514 2/38 516 518 A23L 2/00 F (72) Inventor Kazuki Maruyama 8-1 Kiyohara Industrial Park, Utsunomiya City, Tochigi Pref. MD11 MD14 ME14 4B026 DC05 DG20 DH10 DP10 4B032 DB21 DK18 DL20 4C206 AA01 AA02 DB09 DB48 MA01 MA04 MA72 NA14 ZA06 ZA66 ZA70 ZA75 ZC33 4H059 BA33 BB06
Claims (7)
脂肪酸が１、３位に結合する油脂を、哺乳動物が１日３
０ｍｇ以上を摂取することを可能とする摂取物。Claims: 1. An oil or fat in which an ω-3 fatty acid binds to the 2-position and a medium-chain fatty acid binds to the 1- and 3-positions is used by a mammal for 3 days.
An ingestible substance that allows ingestion of 0 mg or more.
中鎖脂肪酸がカプリル酸である請求項１記載の摂取物。2. The ω-3 fatty acid is docosahexaenoic acid,
The ingestible product according to claim 1, wherein the medium-chain fatty acid is caprylic acid.
求項１または２記載の摂取物。3. The ingestion according to claim 1, wherein the ingestion is intended to enhance exercise endurance.
的とする請求項１または２記載の摂取物。4. The ingested food according to claim 1 or 2 for the purpose of reducing calorie intake or preventing obesity.
治療を目的とする請求項１または２記載の摂取物。5. The ingested product according to claim 1, which is for preventing or treating lifestyle-related diseases such as hyperlipidemia.
請求項１または２記載の摂取物。6. The ingested product according to claim 1, which is for preventing or treating epilepsy.
分泌欠損患者や胆道閉鎖症などの胆汁酸分泌障害患者の
治療または栄養補給を目的とする請求項１または２記載
の摂取物。7. The ingestion according to claim 1, which is for treating or feeding a patient with pancreatic lipase secretion deficiency such as pancreatitis and cystic fibrosis or a bile acid secretion disorder such as biliary atresia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000375386A JP2002180082A (en) | 2000-12-11 | 2000-12-11 | Intake material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000375386A JP2002180082A (en) | 2000-12-11 | 2000-12-11 | Intake material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002180082A true JP2002180082A (en) | 2002-06-26 |
Family
ID=18844402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000375386A Pending JP2002180082A (en) | 2000-12-11 | 2000-12-11 | Intake material |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002180082A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003074042A1 (en) * | 2002-03-04 | 2003-09-12 | The Nisshin Oillio Group, Ltd. | Uncoupling protein expression promoter |
| WO2004085582A2 (en) | 2003-03-27 | 2004-10-07 | Suntory Limited | Lipid-improving agent and composition containing lipid-improving agent |
| JP2007503835A (en) * | 2003-09-05 | 2007-03-01 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Composition for animal consumption. |
| JP2007514733A (en) * | 2003-12-19 | 2007-06-07 | プロノヴァ バイオケア アクティーゼルスカブ | Use of a fatty acid composition comprising at least one of EPA and DHA or any combination thereof |
| JP2008540484A (en) * | 2005-05-12 | 2008-11-20 | プロイェクト、エンプレサリアル、ブルーディ、ソシエダッド、リミターダ | Use of docosahexaenoic acid glycerides for the treatment of neoplastic diseases |
| WO2009056983A1 (en) * | 2007-10-31 | 2009-05-07 | Pronova Biopharma Norge As | New dha derivatives and their use as medicaments |
| JP2010506587A (en) * | 2006-10-17 | 2010-03-04 | エヌ．ブイ．・ヌートリシア | Ketogenic food |
| JP2012100673A (en) * | 2003-07-03 | 2012-05-31 | Hill's Pet Nutrition Inc | Composition and method for decreasing age-related deterioration in mental activity in companion animal |
| US8399516B2 (en) | 2006-11-01 | 2013-03-19 | Pronova Biopharma Norge As | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR) |
| WO2013108428A1 (en) * | 2012-01-19 | 2013-07-25 | 日本水産株式会社 | Appetite suppressant |
| US8618165B2 (en) | 2005-05-04 | 2013-12-31 | Pronova Biopharma Norge As | Compounds |
| US8715717B2 (en) | 2003-09-05 | 2014-05-06 | Hill's Pet Nutrition, Inc. | Composition for animal consumption |
| WO2016010103A1 (en) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | Baked confectionery that substantially includes no flour |
| US10548866B2 (en) * | 2010-11-26 | 2020-02-04 | Ucl Business Ltd | Therapeutic use of compounds |
| CN113924001A (en) * | 2019-02-22 | 2022-01-11 | 米克罗皮公司 | Food supplement |
| WO2024009986A1 (en) * | 2022-07-04 | 2024-01-11 | 株式会社ニッスイ | Endurance-improving agent |
-
2000
- 2000-12-11 JP JP2000375386A patent/JP2002180082A/en active Pending
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003074042A1 (en) * | 2002-03-04 | 2003-09-12 | The Nisshin Oillio Group, Ltd. | Uncoupling protein expression promoter |
| JP2006521368A (en) * | 2003-03-27 | 2006-09-21 | サントリー株式会社 | Lipid improving agent and composition comprising lipid improving agent |
| KR101199599B1 (en) | 2003-03-27 | 2012-11-12 | 산토리 홀딩스 가부시키가이샤 | Lipid-improving agent and composition containing lipid-improving agent |
| US7723386B2 (en) | 2003-03-27 | 2010-05-25 | Suntory Holdings Limited | Lipid-improving agent and composition containing lipid-improving agent |
| TWI393536B (en) * | 2003-03-27 | 2013-04-21 | Suntory Holdings Ltd | Lipid-improving agent and composition containing lipid-improving agent |
| WO2004085582A3 (en) * | 2003-03-27 | 2004-12-02 | Suntory Ltd | Lipid-improving agent and composition containing lipid-improving agent |
| US8236854B2 (en) | 2003-03-27 | 2012-08-07 | Suntory Holdings Limited | Lipid-improving agent and composition containing lipid-improving agent |
| KR101362989B1 (en) | 2003-03-27 | 2014-02-17 | 산토리 홀딩스 가부시키가이샤 | Lipid-improving agent and composition containing lipid-improving agent |
| WO2004085582A2 (en) | 2003-03-27 | 2004-10-07 | Suntory Limited | Lipid-improving agent and composition containing lipid-improving agent |
| EP1605768A2 (en) * | 2003-03-27 | 2005-12-21 | Suntory Limited | Lipid-improving agent and composition containing lipid-improvimg agent |
| JP2012100673A (en) * | 2003-07-03 | 2012-05-31 | Hill's Pet Nutrition Inc | Composition and method for decreasing age-related deterioration in mental activity in companion animal |
| JP2007503835A (en) * | 2003-09-05 | 2007-03-01 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Composition for animal consumption. |
| US8715717B2 (en) | 2003-09-05 | 2014-05-06 | Hill's Pet Nutrition, Inc. | Composition for animal consumption |
| JP2007514733A (en) * | 2003-12-19 | 2007-06-07 | プロノヴァ バイオケア アクティーゼルスカブ | Use of a fatty acid composition comprising at least one of EPA and DHA or any combination thereof |
| US9282760B2 (en) | 2003-12-19 | 2016-03-15 | Pronova Biopharma Norge As | Use of a fatty acid composition comprising at least one of EPA and DHA or any combinations thereof |
| US8618165B2 (en) | 2005-05-04 | 2013-12-31 | Pronova Biopharma Norge As | Compounds |
| JP2008540484A (en) * | 2005-05-12 | 2008-11-20 | プロイェクト、エンプレサリアル、ブルーディ、ソシエダッド、リミターダ | Use of docosahexaenoic acid glycerides for the treatment of neoplastic diseases |
| JP2010506587A (en) * | 2006-10-17 | 2010-03-04 | エヌ．ブイ．・ヌートリシア | Ketogenic food |
| US8399516B2 (en) | 2006-11-01 | 2013-03-19 | Pronova Biopharma Norge As | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR) |
| WO2009056983A1 (en) * | 2007-10-31 | 2009-05-07 | Pronova Biopharma Norge As | New dha derivatives and their use as medicaments |
| JP2011502113A (en) * | 2007-10-31 | 2011-01-20 | プロノヴァ バイオファーマ ノルゲ アーエス | Novel DHA derivatives and their use as pharmaceuticals |
| US10548866B2 (en) * | 2010-11-26 | 2020-02-04 | Ucl Business Ltd | Therapeutic use of compounds |
| US11491127B2 (en) * | 2010-11-26 | 2022-11-08 | Ucl Business Plc | Therapeutic use of compounds |
| US11419839B2 (en) | 2010-11-26 | 2022-08-23 | Ucl Business Ltd | Therapeutic use of compounds |
| JPWO2013108428A1 (en) * | 2012-01-19 | 2015-05-11 | 日本水産株式会社 | Appetite suppressant |
| JP2017039744A (en) * | 2012-01-19 | 2017-02-23 | 日本水産株式会社 | Appetite suppressant |
| WO2013108428A1 (en) * | 2012-01-19 | 2013-07-25 | 日本水産株式会社 | Appetite suppressant |
| JPWO2016010103A1 (en) * | 2014-07-17 | 2017-04-27 | 日清オイリオグループ株式会社 | Baked confectionery substantially free of flour |
| KR101791622B1 (en) | 2014-07-17 | 2017-10-30 | 닛신 오일리오그룹 가부시키가이샤 | Baked confectionery that substantially includes no flour |
| JP5976263B2 (en) * | 2014-07-17 | 2016-08-23 | 日清オイリオグループ株式会社 | Baked confectionery substantially free of flour |
| WO2016010103A1 (en) * | 2014-07-17 | 2016-01-21 | 日清オイリオグループ株式会社 | Baked confectionery that substantially includes no flour |
| CN113924001A (en) * | 2019-02-22 | 2022-01-11 | 米克罗皮公司 | Food supplement |
| WO2024009986A1 (en) * | 2022-07-04 | 2024-01-11 | 株式会社ニッスイ | Endurance-improving agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4870430B2 (en) | Composition for prevention and treatment of varicose veins | |
| US7025984B1 (en) | Compositions and methods for body weight management | |
| RU2376782C2 (en) | Oil composition and food products that contain it, pharmaceutical composition and food additive | |
| JP2002180082A (en) | Intake material | |
| CN103002889B (en) | 2 monoacylglycerols of Sn and lipid malabsorption | |
| WO2006019140A1 (en) | Jelly composition | |
| TWI389697B (en) | Improve the composition of lipid metabolism | |
| JP2006083136A (en) | Composition having action for preventing or ameliorating lowering of cerebral function caused by stress and symptom or disease involving the same lowering | |
| RU2546865C2 (en) | Balanced fat compositions and their application in liquid nutritional compositions for enteral feeding | |
| JP4854253B2 (en) | Composition for improving lipid metabolism | |
| JPH03504868A (en) | Structured lipids containing milk fat | |
| JP2005132758A (en) | Composition having preventing or ameliorating action on symptom or disease caused by blood vessel aging | |
| JP4394174B2 (en) | Inflammatory bowel disease treatment | |
| US20030108600A1 (en) | Ubidecarenone compositions and capsules containing the same | |
| JP2010229099A (en) | Ameliorating or therapeutic drug for dyslipidemia | |
| WO2011128626A1 (en) | Essential fatty acid gelled composition | |
| JP7295812B2 (en) | Lymph circulation improver | |
| JP2000302677A (en) | Medicine and food/feed composition having improving action on carnitine self production ability | |
| WO2021183749A1 (en) | A composition comprising docosahexaenoic acid and egg yolk suitable for sickle cell disease treatment | |
| JP2003516946A (en) | Compositions for improving the proliferative response during gastrointestinal adaptation and use in short bowel syndrome | |
| AU711302C (en) | Nervonic acid compositions | |
| JP2008247791A (en) | Agent for ameliorating liver function | |
| TW201233342A (en) | Methods for decreasing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome in an infant, toddler, or child | |
| JP2003125704A (en) | Edible oil-and-fat composition for alleviating premenstrual syndrome symptom | |
| AU2005242170A1 (en) | Compositions and methods for body weight management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070626 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071023 |